Altimmune, Inc.

Overview

"How the company got here": "Altimmune, Inc. was founded in 1997 and its current public company structure was formed in 2017 through a combination with PharmAthene. Initially, the company focused on vaccines and immunotherapies, including nasal vaccines. However, after facing setbacks in its vaccine programs, Altimmune strategically shifted its focus towards developing treatments for metabolic diseases. A key turning point was the acquisition of Spitfire Pharma, which brought in the drug candidate that would become pemvidutide, now central to the company's strategy. This repositioning has led Altimmune to become a late-stage clinical biopharmaceutical company focused on serious liver diseases." "What it actually does": "Altimmune is a biopharmaceutical company that develops medicines, specifically peptide-based therapies, aimed at treating serious liver diseases and related metabolic conditions. The company's main focus is on its lead drug candidate, pemvidutide, which is currently in late-stage clinical trials. Pemvidutide is designed as a dual-action therapy, meaning it targets two different pathways in the body simultaneously to address the complex nature of liver and metabolic diseases. The company does not currently have any approved products on the market, and its value is primarily based on its clinical trial progress, scientific data, and intellectual property." "Business Lines": "Altimmune is organized as a single, focused biotechnology company, rather than having multiple distinct business units. Its operations are managed through various functional departments like clinical development, regulatory affairs, and manufacturing oversight, all centered around its lead drug candidate, pemvidutide. Therefore, Altimmune essentially operates as one core business line dedicated to developing pemvidutide for various liver and metabolic conditions." "Metabolic Dysfunction-Associated Steatohepatitis (MASH)": "Altimmune is developing pemvidutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition characterized by fat accumulation and inflammation in the liver. MASH is often linked to obesity and insulin resistance, and it can progress to more severe liver damage. Pemvidutide is designed to target both the cause and the consequences of MASH by acting on glucagon and GLP-1 receptors. The company is currently conducting a Phase 3 clinical trial called PERFORMA for MASH, which is a critical step towards seeking regulatory approval. The U.S. Food and Drug Administration (FDA) has granted pemvidutide Fast Track and Breakthrough Therapy Designations for MASH, highlighting the urgent need for new treatments." "Alcohol Use Disorder (AUD)": "Altimmune is also developing pemvidutide for the treatment of alcohol use disorder (AUD), a condition characterized by problematic patterns of alcohol consumption. Pemvidutide's dual-action mechanism, targeting both glucagon and GLP-1 receptors, is being investigated for its potential to help manage AUD. The company has completed Phase 2 clinical trials for AUD, with positive results supporting its continued development. Pemvidutide has received Fast Track Designation from the FDA for AUD, indicating its potential to address a significant unmet medical need." "Alcohol-Associated Liver Disease (ALD)": "Another area Altimmune is targeting with pemvidutide is alcohol-associated liver disease (ALD), which is liver damage caused by excessive alcohol consumption. Pemvidutide's ability to affect liver fat, inflammation, and fibrosis is being studied in the context of ALD. The company is conducting the RESTORE Phase 2 clinical trial for ALD, with a key data readout anticipated in 2027. Similar to its other indications, pemvidutide is being developed to address the underlying mechanisms of ALD." "What management is betting on now": "Altimmune's core strategy is to establish itself as a leading company in the development of therapies for liver and metabolic diseases, with pemvidutide as its central focus. Management is concentrating all efforts on advancing pemvidutide through late-stage clinical trials for MASH, AUD, and ALD. The company recently secured significant financing, providing the necessary capital to fund these critical trials and move closer to potential regulatory approval. Altimmune believes that pemvidutide's unique dual-action mechanism offers a differentiated approach compared to existing treatments, potentially leading to better outcomes for patients."